These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 28349061)

  • 1. Physicochemical and Biological Characterization of the Proposed Biosimilar Tocilizumab.
    Miao S; Fan L; Zhao L; Ding D; Liu X; Wang H; Tan WS
    Biomed Res Int; 2017; 2017():4926168. PubMed ID: 28349061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study comparing the pharmacokinetics and safety of HS628 (tocilizumab biosimilar) and reference tocilizumab in healthy male subjects.
    Qian H; Cheng J; Gui Y; Wang W; Liang L; Zhu H; Wu Q; Ou M; Chen Q; Yu C; Jia J
    Clin Transl Sci; 2023 Sep; 16(9):1704-1712. PubMed ID: 37403258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab.
    Visser J; Feuerstein I; Stangler T; Schmiederer T; Fritsch C; Schiestl M
    BioDrugs; 2013 Oct; 27(5):495-507. PubMed ID: 23649935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Physicochemical and Biological Characterization of the Proposed Biosimilar Darbepoetin Alfa, LBDE, and Its Originator Darbepoetin Alfa, NESP
    Jeong YR; Jeong RU; Son JH; Kwon JC; Jung S; Song MA; Hwang JA; Lee GM
    BioDrugs; 2018 Apr; 32(2):153-168. PubMed ID: 29556960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics.
    Sörgel F; Schwebig A; Holzmann J; Prasch S; Singh P; Kinzig M
    BioDrugs; 2015 Apr; 29(2):123-31. PubMed ID: 25837839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel(®)).
    Hofmann HP; Kronthaler U; Fritsch C; Grau R; Müller SO; Mayer R; Seidl A; Da Silva A
    Expert Opin Biol Ther; 2016 Oct; 16(10):1185-95. PubMed ID: 27463856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABP 501 for the treatment of rheumatoid arthritis.
    Pelechas E; Voulgari PV; Drosos AA
    Expert Opin Biol Ther; 2018 Mar; 18(3):317-322. PubMed ID: 29350566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
    Braun J; Kudrin A
    Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.
    Müller-Ladner U; Hong S; Oh C; Taylor P
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S5-14. PubMed ID: 26395832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
    Gonçalves J; Araújo F; Cutolo M; Fonseca JE
    Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Part 1: Physicochemical characterization of bevacizumab in undiluted 25 mg/mL drug product solutions: Comparison of originator with a biosimilar candidate.
    Arvinte T; Palais C; Poirier E; Cudd A; Rajendran S; Brokx S; Dowd J
    J Pharm Biomed Anal; 2019 Oct; 175():112742. PubMed ID: 31344647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars for psoriasis: clinical studies to determine similarity.
    Blauvelt A; Puig L; Chimenti S; Vender R; Rajagopalan M; Romiti R; Skov L; Zachariae C; Young H; Prens E; Cohen A; van der Walt J; Wu JJ
    Br J Dermatol; 2017 Jul; 177(1):23-33. PubMed ID: 27639072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physicochemical and Biological Characterization of RTXM83, a New Rituximab Biosimilar.
    Cerutti ML; Pesce A; Bès C; Seigelchifer M
    BioDrugs; 2019 Jun; 33(3):307-319. PubMed ID: 30927214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab.
    Liu Y; Xie J; Li Z; Mei X; Cao D; Li S; Engle L; Liu S; Ebbers HC; Liu C
    BioDrugs; 2024 Jul; 38(4):571-588. PubMed ID: 38890199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs.
    Civoli F; Kasinath A; Cai XY; Wadhwa M; Exley A; Oldfield P; Alvandkouhi S; Schaffar G; Chappell J; Bowsher R; Devanarayan V; Marini J; Rebarchak S; Anderson M; Koppenburg V; Lester T
    AAPS J; 2019 Dec; 22(1):7. PubMed ID: 31792633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparability study of Rituximab originator and follow-on biopharmaceutical.
    Montacir O; Montacir H; Eravci M; Springer A; Hinderlich S; Saadati A; Parr MK
    J Pharm Biomed Anal; 2017 Jun; 140():239-251. PubMed ID: 28371718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biosimilars].
    Krämer I
    Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization and pre-clinical assessment of a proposed biosimilar to its originator Omalizumab.
    Wang Y; Zheng C; Zhuang C; Fu Q; Zhang B; Bian Y; Qi N; Zhu J
    Eur J Pharm Sci; 2022 Nov; 178():106292. PubMed ID: 36089232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Total evidence" network meta-analysis as a tool for improving the assessment of biosimilars: application to etanercept in rheumatoid arthritis
.
    Messori A; Trippoli S; Marinai C
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):517-520. PubMed ID: 28372634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.